Suven Life Sciences Ltd

NSE: SUVEN · BSE: 530239 · Healthcare · 3 announcements

Share price: ₹335.00
Market cap: ₹9,466 Cr
Revenue (annual): ₹7.11 Cr
Net profit (annual): ₹-276.3 Cr
P/E (TTM): -26.9×Sector 57.8×
Promoter holding: 65.47%-4.68% QoQ
FII holding: 0.48%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Financial Results 2 Business Update 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

3 announcements

3 Sep 2026 11:56 IST NSE

Business Update

Suven Life Sciences Business Update

Suven Life Sciences has completed patient enrollment for its global Phase-3 clinical study of Masupirdine. A total of 424 patients were randomized across the USA and Europe.

clinical trial enrollment: 424.0 patients

Read the filing ↗

6 Aug 2026 12:47 IST NSE

Financial Results

Suven Life Sciences Q1 FY27 Results: Net Loss of ₹127.6 Cr, Loss Widens

Suven Life Sciences Ltd reported revenue from operations of ₹3.6 Cr (+89.5% YoY) and a net loss of ₹127.6 Cr for Q1 FY27.

Key figure: Net loss ₹127.6 Cr

Open full results → Read the filing ↗

13 May 2026 13:55 IST NSE

Financial Results

Suven Life Sciences Q4 FY26 Results: Net Loss of ₹45.6 Cr, Loss Widens

Suven Life Sciences Ltd reported revenue from operations of ₹1.5 Cr (+0.0% YoY) and a net loss of ₹45.6 Cr for Q4 FY26.

Key figure: Net loss ₹45.6 Cr

Open full results → Read the filing ↗